HC Financial Advisors Inc. purchased a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,061 shares of the medical research company’s stock, valued at approximately $1,924,000. Amgen comprises 1.9% of HC Financial Advisors Inc.’s holdings, making the stock its 22nd biggest holding.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Toronto Dominion Bank boosted its holdings in shares of Amgen by 11.0% during the third quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock worth $52,066,000 after acquiring an additional 27,726 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Amgen by 16.5% during the third quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock worth $138,115,000 after acquiring an additional 104,871 shares during the period. Putnam FL Investment Management Co. bought a new stake in shares of Amgen during the third quarter worth approximately $447,000. Moody Lynn & Lieberson LLC bought a new stake in shares of Amgen during the third quarter worth approximately $2,353,000. Finally, Patten Group Inc. boosted its holdings in shares of Amgen by 1,151.5% during the third quarter. Patten Group Inc. now owns 27,859 shares of the medical research company’s stock worth $389,000 after acquiring an additional 25,633 shares during the period. 79.53% of the stock is currently owned by hedge funds and other institutional investors.
Shares of AMGN stock opened at $170.48 on Monday. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. The company has a market capitalization of $122,841.44, a P/E ratio of 13.55, a P/E/G ratio of 2.09 and a beta of 1.36. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23.
Amgen announced that its board has authorized a stock repurchase program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 3.10%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 41.97%.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 4,575 shares of company stock valued at $838,064. 0.19% of the stock is currently owned by corporate insiders.
A number of equities research analysts have recently issued reports on AMGN shares. Oppenheimer restated a “buy” rating and set a $205.00 price objective on shares of Amgen in a report on Tuesday, January 30th. Argus upgraded Amgen from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $192.33 to $220.00 in a report on Tuesday, January 23rd. Piper Jaffray restated a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Mizuho set a $192.00 price objective on Amgen and gave the stock a “buy” rating in a report on Thursday, December 28th. Finally, Goldman Sachs cut Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $191.26.
ILLEGAL ACTIVITY NOTICE: This story was reported by WKRB News and is the property of of WKRB News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.wkrb13.com/2018/04/02/hc-financial-advisors-inc-purchases-shares-of-11061-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.